Legend Biotech posts $657M CARVYKTI sales

Legend Biotech reports preliminary commercial performance for CARVYKTI® under its collaboration with Janssen.

Rhea-AI Filing Summary

Legend Biotech reports preliminary commercial performance for CARVYKTI® under its collaboration with Janssen. Based on data provided by Janssen, CARVYKTI® generated approximately $657 million in net trade sales for the quarter ended June 30, 2026. This figure has not been independently verified by Legend Biotech, and the final amount of revenue and gross profit to be recognized in Legend Biotech’s financial statements will be determined after management completes the preparation of its results for the period. Legend Biotech’s independent registered public accountants have not audited, reviewed or performed procedures on this sales data.

The company includes forward-looking statements about expectations for CARVYKTI® net trade sales and resulting gross profit, noting that actual results may differ materially due to factors such as drug development risks, unexpected clinical or regulatory outcomes, partner actions, intellectual property challenges including U.S. litigation, competition, and pricing and political pressures. These risks are further described in the Risk Factors section of Legend Biotech’s Annual Report on Form 20-F filed on March 10, 2026. This report is also incorporated by reference into Legend Biotech’s existing Form F-3 and Form S-8 registration statements, to the extent not superseded by later filings.

Key Figures

CARVYKTI net trade sales: $657 million Collaboration agreement date: December 21, 2017 Quarter end date: June 30, 2026 +2 more

5 metrics

CARVYKTI net trade sales $657 million Approximate net trade sales for the quarter ended June 30, 2026

Collaboration agreement date December 21, 2017 Effective date of the Collaboration and License Agreement for CARVYKTI

Quarter end date June 30, 2026 End of the quarter for which preliminary CARVYKTI sales are reported

Form 20-F filing date March 10, 2026 Date of the Annual Report referenced for Risk Factors

Form 6-K report date July 15, 2026 Date of the report of foreign private issuer

Key Terms

net trade sales, Collaboration and License Agreement, forward-looking statements, independent registered public accountants, +1 more

5 terms

net trade sales financial

"CARVYKTI® generated approximately $657 million in net trade sales during the quarter"

Collaboration and License Agreement regulatory

"Pursuant to the Collaboration and License Agreement dated as of December 21, 2017"

A collaboration and license agreement is a legal contract where two or more parties agree to work together on developing or selling a product or technology while granting one another specific rights to use patents, know‑how, or other intellectual property. For investors, it matters because such deals can bring upfront payments, milestone or royalty income, and shared development costs and risks—like two neighbors pooling tools to renovate a house, which can speed progress and change future revenue potential.

forward-looking statements regulatory

"constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

independent registered public accountants financial

"Legend Biotech’s independent registered public accountants have not audited, reviewed or performed any procedures"

Independent registered public accountants are external auditing firms licensed to examine a public company’s financial records and issue an objective opinion on whether the financial statements are accurate and follow accounting rules. They matter to investors because their independent check is like a neutral referee confirming the score in a game — it reduces the risk of errors or misleading information and helps investors trust the financial reports used to make decisions.

Risk Factors regulatory

"as well as the other factors discussed in the “Risk Factors” section of the Legend Biotech’s Annual Report"

Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What preliminary CARVYKTI sales did Legend Biotech (LEGN) report for Q2 2026?

Legend Biotech reported that CARVYKTI® generated approximately $657 million in net trade sales for the quarter ended June 30, 2026. The figure comes from Janssen and is preliminary, unaudited, and subject to change when Legend Biotech finalizes its financial statements.

How will CARVYKTI sales be reflected in Legend Biotech (LEGN) financial results?

The reported $657 million net trade sales will not directly equal Legend Biotech’s revenue. Management will determine the revenue and gross profit to record once financial statements for the period ended June 30, 2026 are completed, and these amounts may differ from net trade sales.

What is the collaboration between Legend Biotech (LEGN) and Janssen for CARVYKTI?

CARVYKTI® is developed and commercialized under a Collaboration and License Agreement dated December 21, 2017, as amended, among Legend Biotech USA Inc., Legend Biotech Ireland Limited, Janssen Biotech, Inc. and Janssen Pharmaceutica NV. Janssen provides the underlying sales information used by Legend Biotech.

Are the reported CARVYKTI sales for Legend Biotech (LEGN) audited or reviewed?

No. The CARVYKTI® sales figure is based on information from Janssen, has not been independently verified by Legend Biotech, and Legend Biotech’s independent registered public accountants have not audited, reviewed or performed procedures on this data.

What risks could affect CARVYKTI results for Legend Biotech (LEGN)?

Legend Biotech highlights risks including drug development uncertainties, unexpected clinical data, regulatory actions or delays, partner actions, intellectual property challenges including U.S. litigation, competition, and pricing and political pressures, along with other risks described in the Risk Factors section of its Form 20-F filed March 10, 2026.

How is this Legend Biotech (LEGN) CARVYKTI sales update used in its registrations?

This report is incorporated by reference into Legend Biotech’s existing Form F-3 (Nos. 333-278050 and 333-257625) and Form S-8 (Nos. 333-239478 and 333-283217) registration statements, to the extent not superseded by later filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/15/2026 - 07:30 AM Accepted by SEC EDGAR 07/15/2026 - 07:30 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

Date of Report: July 15, 2026

Commission File Number: 001-39307

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

77 Corporate Drive

Bridgewater, New Jersey 08807

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒            Form 40-F  ☐

Legend Biotech Announces Preliminary Sales for CARVYKTI^® for the Quarter Ended June 30, 2026

Pursuant to the Collaboration and License Agreement dated as of December 21, 2017, as amended, between Legend Biotech USA Inc., Legend Biotech Ireland Limited, Janssen Biotech, Inc. and Janssen Pharmaceutica NV (together, “Janssen”), on July 15, 2026, Legend Biotech Corporation (“Legend Biotech”) announced that CARVYKTI^® generated approximately $657 million in net trade sales during the quarter ended June 30, 2026. The net trade sales figure is based on information provided to Legend Biotech by Janssen, and Legend Biotech has not independently verified the accuracy of such sales figure.

The sales figure is based on information available to Legend Biotech as of the date of this Form 6-K, and the determination of the amount of any revenue or gross profit to be recorded in Legend Biotech’s consolidated statement of operations is subject to completion by management of Legend Biotech of its financial statements as of and for the period ended June 30, 2026. Legend Biotech’s independent registered public accountants have not audited, reviewed or performed any procedures with respect to this data and accordingly they have not expressed an opinion or provided any other form of assurance with respect thereto.

Cautionary Note Regarding Forward-Looking Statements

Statements in this report on Form 6-K about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to CARVYKTI^®, including Legend Biotech’s expectations for net trade sales and resulting gross profit of CARVYKTI^®. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general public pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of the Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2026. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Form 6-K as anticipated, believed, estimated or expected. Any forward-looking statements contained in this Form 6-K speak only as of the date of this Form 6-K. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

This report on Form 6-K is hereby incorporated herein by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-278050 and 333-257625) and Form S-8 (No. 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		LEGEND BIOTECH CORPORATION
Date:  July 15, 2026		By:	/s/ Ying Huang
		Name:	Ying Huang, Ph.D.
		Title:	Chief Executive Officer